Q1 2023 Results
Company overview
Innovation: Pipeline overview
Financial review
Financial performance
Cardiovascular
Immunology
Ophthalmology
BeovuⓇ - VEGF Inhibitor
NCT04278417 CONDOR (CRTH258D2301)
Indication
Diabetic retinopathy
Phase
Phase 3
Patients
694
Primary
Change from Baseline in BCVA
Outcome
Measures
Arms
Conclusions
Intervention
Target
Patients
Arm 1: RTH258 (brolucizumab) 6 mg/50uL
Arm 2: Panretinal photocoagulation laser initial treatment followed with
additional PRP treatment as needed
Patients with proliferative diabetic retinopathy
Readout
Milestone(s)
Publication
2024
TBD
Neuroscience
Global Health
Appendix
Innovation: Clinical trials
References
Abbreviations
Oncology
Other
Biosimilars
84 Investor Relations | Q1 2023 Results
1 NOVARTIS | Reimagining MedicineView entire presentation